Ajaykumar D. Rao, MD, MMSc, FACP, Chief of the Section of Endocrinology, Diabetes and Metabolism and Associate Professor of Medicine at the Lewis Katz School of Medicine at Temple University and Associate Professor in the Center for Metabolic Disease Research at Temple University Hospital, provided perspective to Healthline on new research that found semaglutide (also known as Wegovy or Ozempic) may help lower the risk of developing cardiovascular disease. The research, presented at the European Congress on Obesity, found that multiple cardiovascular risk factors, including blood pressure, total cholesterol and triglycerides, decreased after a year of taking semaglutide. Dr. Rao was not involved in the study.
Temple Faculty Physicians is experiencing technical issues with phone lines. If you are experiencing an emergency, please visit your nearest emergency room. If you would like to schedule an appointment with your provider or have general questions or requests, please contact us by using myTempleHealth.
myTempleHealth
800-TEMPLE-MED
Schedule Appointment
SEARCH TEMPLE HEALTH